Literature DB >> 32971206

Type 2 cytokines IL-4 and IL-5 reduce severe outcomes from Clostridiodes difficile infection.

Alexandra N Donlan1, Morgan E Simpson2, William A Petri3.   

Abstract

Clostridiodes difficile infection (CDI) is the leading cause of hospital-acquired gastrointestinal infections in the U.S. While the immune response to C. difficile is not well understood, it has been shown that severe disease is accompanied by high levels of infiltrating immune cells and pro-inflammatory cytokine production. This study tests the roles of two type 2 cytokines, IL-4 and IL-5, in mediating protection in a murine model of disease. Administration of IL-5 protected from mortality due to CDI, and both IL-4 and IL-5 were protective against severe disease symptoms. Together, the results from this study increase our understanding of how type 2 immune signaling processes are protective from severe C. difficile infection.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  C. difficile; Cytokines; Type 2 immunity

Year:  2020        PMID: 32971206      PMCID: PMC7736165          DOI: 10.1016/j.anaerobe.2020.102275

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  3 in total

1.  Loss of Interleukin-10 (IL-10) Signaling Promotes IL-22-Dependent Host Defenses against Acute Clostridioides difficile Infection.

Authors:  Emily S Cribas; Joshua E Denny; Jeffrey R Maslanka; Michael C Abt
Journal:  Infect Immun       Date:  2021-04-16       Impact factor: 3.441

Review 2.  Host Immune Responses to Clostridioides difficile: Toxins and Beyond.

Authors:  Britt Nibbering; Dale N Gerding; Ed J Kuijper; Romy D Zwittink; Wiep Klaas Smits
Journal:  Front Microbiol       Date:  2021-12-21       Impact factor: 5.640

3.  Interleukin-4 protects mice against lethal influenza and Streptococcus pneumoniae co-infected pneumonia.

Authors:  Yang Peng; Xiaofang Wang; Hong Wang; Wenchun Xu; Kaifeng Wu; Xuemei Go; Yibing Yin; Xuemei Zhang
Journal:  Clin Exp Immunol       Date:  2021-07-07       Impact factor: 5.732

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.